ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Prostate Cancer

Prostate Cancer

A randomized phase III trial found that a hypofractionated radiotherapy regimen was not superior to, but generally equivalent to a conventional radiotherapy scheme in men with localized prostate cancer.

A database analysis showed that the addition of external beam radiotherapy to ADT significantly improves overall survival in men with metastatic prostate cancer.

Higher than average PSA levels in middle age may be predictive of a higher risk of lethal prostate cancer later in life.

In this peer-to-peer discussion, Dr. Loeb and Dr. Choyke discuss new developments in active surveillance for prostate cancer.

Experimental, minimally invasive “liquid biopsy” blood tests might soon help to personalize prostate cancer treatment by predicting androgen resistance and survival benefits from particular treatments.

Use of multiparametric MRI could allow a significant portion of men with elevated PSA levels to avoid undergoing a biopsy without missing clinically significant prostate cancers.

The use of ADT along with modern dose-escalated RT does not improve survival vs RT alone in men with favorable intermediate-risk prostate cancer.

Pages

Subscribe to Prostate Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.